~~<i id='E09477F408'><strike id='E09477F408'><tt id='E09477F408'><pre id='E09477F408'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

knowledge

author：knowledge 2025-09-30 09:31:01 - browse：235

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： See how much Covid

Wikipedia

hotspot

entertainment

explore

entertainment

LaurieGlimcher,CEOofDanaFarberCancerInstitute,isthearchitectofthebiggestshakeupinBostonhealthcareind

WSS

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO: Palliative care found as helpful given virtually as in person

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

STAT letters to the editor on burnt

Cord blood banking comes at a high cost to babies

Americans' trust in science, scientist continues decline: Report

entertainment

knowledge

Wikipedia

How to save PrEP access — and even expand it

Woman returns to dialysis after doctors remove transplanted pig kidney

How one medical school became remarkably diverse

In diabetes hearing, Sanders takes on a new foe: food makers

Sports medicine is finally prioritizing gender equality

CMS should re

Anesthesiologist group: stop taking Ozempic before surgery

NIH documents show early flaws of $1.6 billion long Covid program

Medical records are filled with copy

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Wikipedia

Shifting the focus from loneliness to social health

Patients' immediate access to test results puts radiologists in a bind

Chemotherapy shortages won’t get better under Biden’s latest plan

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

The woman behind the Dana Farber

What causes an itch? Researchers may have solved the mystery

hotspot

entertainment

explore

entertainment